ENDPOINTS

FDA approves Sanofi's RNAi drug for hemophilia A and B

The FDA on Friday said it approved a new RNAi-based hemophilia treatment from Sanofi that the company licensed from Alnylam. Patients with hemophilia A or B will now be able to ...

Mar 28, 2025 - 19:48
 0
FDA approves Sanofi's RNAi drug for hemophilia A and B
The FDA on Friday said it approved a new RNAi-based hemophilia treatment from Sanofi that the company licensed from Alnylam. Patients with hemophilia A or B will now be able to ...
Read More

Tags:

Previous Article

At long last, Novartis’ radiopharma drug Pluvicto gets an expanded label

Next Article

Solar eclipse US weather forecast: Best places to see the moon 'bite' the sun to...

Related Posts

UPDATED: Moderna earnings: Losses narrow as biotech cuts costs

UPDATED: Moderna earnings: Losses narrow as biotech cut...

Feb 14, 2025  0

Boehringer Ingelheim touts success in second Phase 3 lung fibrosis trial

Boehringer Ingelheim touts success in second Phase 3 lu...

Feb 10, 2025  0

China bans imports of Illumina's DNA sequencers following US tariffs

China bans imports of Illumina's DNA sequencers followi...

Mar 4, 2025  0